Postmenopausal hormone therapy and cardiovascular disease in perspective

Clinical Obstetrics and Gynecology

Volumn 51, Issue 3, 2008, Pages 564-580

  Hodis, Howard N ^a   MacK, Wendy J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Coronary heart disease; Hormone therapy; Menopause

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; GESTODENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; PLACEBO; PRAVASTATIN;

ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HEART INFARCTION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MORTALITY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIMARY PREVENTION; TREATMENT DURATION; AGE; ESTROGEN THERAPY; FEMALE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

AGE FACTORS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 54449086529     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318181de86     Document Type: Article

References (52)

1. GrodsteinF,StampferM.The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.Prog Cardiol Dis. 1995;38: 199-210.
2. Grodstein F, Stampfer M. Estrogen for women at varying risk of coronary disease. Maturitas. 1998;30:19-26.
3. Prentice RL, Langer R, Stefanick ML, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone therapy and cardiovascular disease. Am J Epidemiol. 2006;163:589-599.
4. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health. 1989;43:173-178.
5. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogenprogestogen replacement. Br J Obstet Gynaecol. 1992;99:821-828.
6. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med. 1994;154: 1333-1339.
7. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
8. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol. 2005;162:404-414. 9. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
9. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischemic heart disease: the Papworth HRT Atherosclerosis Study. BJOG. 2002; 109:1056-1062.
10. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for the prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet. 2002;360:2001-2008.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321-323.
12. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
13. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
14. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166: 357-365.
15. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 2000; 343:522-529.
16. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopau-sal women. JAMA. 2002;288:2432-2440.
17. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med. 2003; 349:535-545.
18. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;135:939-953.
19. Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2001;21: 262-268.
20. Hodis HN, Mack WJ, Lobo R. What is the cardioprotective role of hormone replacement therapy? Curr Atheroscler Rep. 2003;5:56-66.
21. Rossouw JE, Prentice RL, Manson JA, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297:1465-1477.
22. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health. 2006;15: 35-44.
23. Salpeter SR, Walsh JME, Greyber E, et al. Coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2006;21: 363-366.
24. Henderson BD, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151:75-78.
25. Salpeter SR, Walsh JME, Greyber E, et al. Mortality associated with hormone replacement therapy inyounger and older women: a meta-analysis. J Gen Intern Med. 2004;19:791-804.
26. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
27. Blankenhorn DH, Hodis HN. Duff Memorial Lecture: arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 1994;14:177-192.
28. de Kleijn MJJ, Bots ML, Bak AAA, et al. Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness. Maturitas. 1999;32:195-204.
29. Hodis HN, Mack WJ. Randomized controlled trials and the effects of post-menopausal hormone therapy on cardiovascular disease: facts, hypotheses and clinical perspective. In: Lobo RA, ed. Treatment of the Postmenopausal Woman. 3rd ed. Philadelphia, PA: Elsevier; 2007:529-564.
30. Chilvers CED, Knibb RC, Armstrong SJ, et al. Postmenopausal hormone replacement therapy and risk of acute myocardial infarction: a case control study of women in the East Midlands, UK. Eur Heart J. 2003;24:2197-2205.
31. Heckbert SR, Weiss NS, Koepsell TD, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med. 1997;157: 1330-1336.
32. FerraraA,QuesenberryCP, Karter AJ, et al. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente diabetes registry, 1995 to 1998. Circulation. 2003; 107:43-48.
33. Akhrass F, Evans AT, Wang Y, et al. Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab. 2003;88:5611-5614.
34. Barrett-Connor E, Laughlin GA. Hormone therapy and coronary artery calcification in asymptomatic post-menopausal women: the Rancho Bernardo Study. Menopause. 2005;12:40-48.
35. Hodis HN, Mack WJ. Postmenopausal hormone therapy in clinical perspective. Menopause. 2007;14:944-957.
36. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
37. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109:672-693.
38. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004; 291:2243-2252.
39. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
40. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.
41. Bonovas S, Filioussi K, Tsavaris N, et al. Use of statins and breast cancer: a metaanalysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23:8606-8612.
42. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006; 295:1647-1657.
43. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289: 3243-3253.
44. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55:103-115.
45. ShepherdJ,Blauw GJ, Murphy MB,etal. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360: 1623-1630.
46. Clearfield M, Downs JR, Weis S, et al. Air force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001; 10:971-981.
47. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288: 2998-3007.
48. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetyl-salicylic acid: the HOT study. J Hypertens. 2000;18:629-642.
49. Collaborative group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet. 2001;357:89-95.
50. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. preventive services task force. Ann Intern Med. 2002;136:161-172.
51. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1984;321:129-135.
52. Nelson HD, Vesco KK, Haney E, et al. Nonhumoral therapies for menopausal hot flashes: systematic review and metaanalysis. JAMA. 2006;295:2057-2071.